雷米普利联合拜新同治疗女性更年期高血压患者的临床效果及对血压波动的影响研究(1)
【摘要】 目的 探討雷米普利联合硝苯地平控释片(商品名：拜新同)治疗女性更年期高血压患者的临床效果及对血压波动的影响。方法 90例女性更年期高血压患者， 根据治疗方法不同分为对照组与观察组， 各45例。对照组接受雷米普利治疗， 观察组在对照组基础上联合拜新同治疗。对比两组患者治疗前后激素水平、全天血压水平、临床疗效以及治疗前后症状自评量表(SCL-90)评分。结果 治疗前， 两组患者黄体生成素、卵泡刺激素、血清雌二醇水平对比， 差异无统计学意义(P>0.05);治疗后， 观察组患者黄体生成素、卵泡刺激素、血清雌二醇水平分别为(10.34±1.67)IU/L、(31.69±2.48)IU/L、(66.47±13.14)ng/L， 均优于对照组的(27.90±1.58)IU/L、(56.25±2.63)IU/L、(47.52±13.25)ng/L， 差异具有统计学意义(P<0.05)。两组患者白天、夜间、全天的SBP、DBP水平对比， 差异具有统计学意义(P<0.05)。观察组患者总有效率95.56%高于对照组的68.89%， 差异具有统计学意义(P<0.05)。治疗前， 两组患者SCL-90评分对比， 差异无统计学意义(P>0.05);治疗后， 两组患者SCL-90评分均低于治疗前， 且观察组SCL-90评分(99.34±19.22)分低于对照组的(142.34±22.10)分， 差异具有统计学意义(P<0.05)。结论 雷米普利联合拜新同治疗女性更年期高血压患者， 可有效稳定激素和血压水平， 提高临床疗效， 促进生存质量改善， 分析其原因是两种药物具有不同作用机制， 发挥了协同作用， 值得临床推广。
【关键词】 雷米普利;硝苯地平控释片;女性;更年期高血压;临床效果;血压波动
【Abstract】 Objective To discuss the clinical effect of ramipril combined with nifedipine controlled release tablets (trade name： Baixintong) in the treatment of female climacteric hypertension and its influence on blood pressure fluctuation. Methods A total of 90 female patients with climacteric hypertension were divided into control group and observation group， with 45 cases in each group. The control group was treated by ramipril， and the observation group was treated by Baixintong on the basis of the control group. The hormone level before and after treatment， blood pressure level throughout the day， clinical effect and symptom checklist (SCL-90) score before and after treatment was compared between the two groups. Results Before treatment， there was no statistically significant difference in luteinizing hormone， follicle stimulating hormone and serum estradiol levels between the two groups (P>0.05). After treatment， the luteinizing hormone， follicle stimulating hormone and serum estradiol levels were (10.34±1.67) IU/L， (31.69±2.48) IU/L and (66.47±13.14) ng/L in the observation group， which was better than (27.90±1.58) IU/L， (56.25±2.63) IU/L and (47.52±13.25) ng/L in the control group， and their difference was statistically significant (P<0.05). There was statistically significant difference in systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels in daytime， night and throughout the day between the two groups (P<0.05). The total effective rate 95.56% in the observation group was higher than 68.89% in the control group， and the difference was statistically significant (P<0.05). Before treatment， there was no statistically significant difference in SCL-90 score between the two groups (P>0.05). After treatment， the SCL-90 score in the two groups was lower than those before treatment， and the SCL-90 score (99.34±19.22) points in the observation group was lower than (142.34±22.10) points in the control group. Their difference was statistically significant (P<0.05). Conclusion For the treatment of female climacteric hypertension， Remipril combined with Baixinton can effectively stabilize hormone and blood pressure levels， improve clinical efficacy and improve the quality of life. The reason is that the two drugs have different mechanisms of action and play a common role， which is worthy of clinical promotion., 百拇医药(马海红)
【关键词】 雷米普利;硝苯地平控释片;女性;更年期高血压;临床效果;血压波动
【Abstract】 Objective To discuss the clinical effect of ramipril combined with nifedipine controlled release tablets (trade name： Baixintong) in the treatment of female climacteric hypertension and its influence on blood pressure fluctuation. Methods A total of 90 female patients with climacteric hypertension were divided into control group and observation group， with 45 cases in each group. The control group was treated by ramipril， and the observation group was treated by Baixintong on the basis of the control group. The hormone level before and after treatment， blood pressure level throughout the day， clinical effect and symptom checklist (SCL-90) score before and after treatment was compared between the two groups. Results Before treatment， there was no statistically significant difference in luteinizing hormone， follicle stimulating hormone and serum estradiol levels between the two groups (P>0.05). After treatment， the luteinizing hormone， follicle stimulating hormone and serum estradiol levels were (10.34±1.67) IU/L， (31.69±2.48) IU/L and (66.47±13.14) ng/L in the observation group， which was better than (27.90±1.58) IU/L， (56.25±2.63) IU/L and (47.52±13.25) ng/L in the control group， and their difference was statistically significant (P<0.05). There was statistically significant difference in systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels in daytime， night and throughout the day between the two groups (P<0.05). The total effective rate 95.56% in the observation group was higher than 68.89% in the control group， and the difference was statistically significant (P<0.05). Before treatment， there was no statistically significant difference in SCL-90 score between the two groups (P>0.05). After treatment， the SCL-90 score in the two groups was lower than those before treatment， and the SCL-90 score (99.34±19.22) points in the observation group was lower than (142.34±22.10) points in the control group. Their difference was statistically significant (P<0.05). Conclusion For the treatment of female climacteric hypertension， Remipril combined with Baixinton can effectively stabilize hormone and blood pressure levels， improve clinical efficacy and improve the quality of life. The reason is that the two drugs have different mechanisms of action and play a common role， which is worthy of clinical promotion., 百拇医药(马海红)
参见：首页 > 保健版 > 家庭健康 > 中年保健 > 更年期